Vertex Pharmaceuticals Incorporated
VRTX
$435.52
$1.500.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.08B | 2.94B | 2.76B | 2.91B | 2.77B |
| Total Other Revenue | -- | 20.70M | 10.00M | -- | -- |
| Total Revenue | 3.08B | 2.96B | 2.77B | 2.91B | 2.77B |
| Cost of Revenue | 1.39B | 1.39B | 1.34B | 1.42B | 1.27B |
| Gross Profit | 1.68B | 1.58B | 1.43B | 1.49B | 1.50B |
| SG&A Expenses | 445.10M | 424.60M | 396.40M | 377.60M | 371.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.84B | 1.81B | 1.74B | 1.80B | 1.64B |
| Operating Income | 1.24B | 1.15B | 1.03B | 1.11B | 1.13B |
| Income Before Tax | 1.30B | 1.28B | 730.40M | 1.14B | 1.22B |
| Income Tax Expenses | 215.90M | 250.10M | 84.10M | 223.50M | 178.70M |
| Earnings from Continuing Operations | 1.08B | 1.03B | 646.30M | 913.00M | 1.05B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.08B | 1.03B | 646.30M | 913.00M | 1.05B |
| EBIT | 1.24B | 1.15B | 1.03B | 1.11B | 1.13B |
| EBITDA | 1.29B | 1.21B | 1.08B | 1.13B | 1.18B |
| EPS Basic | 4.24 | 4.02 | 2.52 | 3.55 | 4.05 |
| Normalized Basic EPS | 3.31 | 3.12 | 2.79 | 2.96 | 3.00 |
| EPS Diluted | 4.20 | 3.99 | 2.49 | 3.50 | 4.01 |
| Normalized Diluted EPS | 3.28 | 3.09 | 2.76 | 2.93 | 2.96 |
| Average Basic Shares Outstanding | 255.60M | 256.70M | 256.90M | 257.50M | 258.00M |
| Average Diluted Shares Outstanding | 257.60M | 258.90M | 259.50M | 260.50M | 261.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |